The estimated Net Worth of Nevelle J Jeharajah is at least $5.01 Milión dollars as of 1 August 2003. Nevelle Jeharajah owns over 5,000 units of Baxter International stock worth over $5,010,970 and over the last 22 years Nevelle sold BAX stock worth over $0.
Nevelle has made over 1 trades of the Baxter International stock since 2003, according to the Form 4 filled with the SEC. Most recently Nevelle bought 5,000 units of BAX stock worth $140,350 on 1 August 2003.
The largest trade Nevelle's ever made was buying 5,000 units of Baxter International stock on 1 August 2003 worth over $140,350. On average, Nevelle trades about 278 units every 0 days since 2003. As of 1 August 2003 Nevelle still owns at least 127,603 units of Baxter International stock.
You can see the complete history of Nevelle Jeharajah stock trades at the bottom of the page.
Nevelle's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney a Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: